In a notable bipartisan move, Representative Ro Khanna (D-CA) has endorsed President Donald Trump’s executive order aimed at reducing prescription drug prices in the United States. Khanna announced his support on social media, stating, “I support @realDonaldTrump’s effort to ensure Americans do not pay more for drugs than those in other countries.” He further proposed introducing legislation to codify the executive order into law, emphasizing the need for a permanent solution to high drug costs.
President Trump’s executive order, signed on May 12, 2025, implements a “Most Favored Nation” policy, tying U.S. drug prices to those in other countries that often pay significantly less due to negotiated pricing systems. The order directs Health Secretary Robert F. Kennedy Jr. to negotiate price reductions with drug manufacturers within 30 days, with the potential for regulatory action if no progress is made in 180 days.
Khanna’s support is rooted in the belief that legislative action is necessary to withstand potential legal challenges from the pharmaceutical industry. He stated, “Instead of an EO that will get challenged again by Big Pharma, why not work with @BernieSanders & me to make this law,” reported National Desk.
Senator Bernie Sanders (I-VT) echoed Khanna’s sentiments, expressing support for the executive order but emphasizing the importance of legislative backing to ensure its durability. Sanders remarked, “If Trump is serious about making real change rather than just issuing a press release, he will support legislation I will introduce to ensure we pay no more for prescription drugs than people in other major countries,” reported Trending Politics.
The pharmaceutical industry has voiced concerns over the executive order, arguing that government-imposed price controls could hinder innovation and competitiveness. However, proponents argue that aligning U.S. drug prices with those of other countries is a necessary step to alleviate the financial burden on American consumers.
